Follow the progress of Hemolens Diagnostics
This website contains information intended only for persons professionally dealing with medical devices (e.g. for persons performing medical professions, for persons dealing with the distribution of medical devices). Please confirm that you are a medical device professional to proceed.
Follow the progress of Hemolens Diagnostics
June 23, 2023
Warsaw, 22 June 2023. – Wrocław-based Hemolens Diagnostics has been awarded this year’s “Polonica Progressio” award by the Minister of Development and Technology for its innovative solution in the field of non-invasive coronary artery disease diagnostics.
This is the second edition of the award, and Minister Waldemar Buda’s initiative aims to honor businesses that have made a significant contribution to the development and promotion of the Polish economy. The award is intended to recognize work and engagement in building the brand of Poland in the world and enhancing the competitiveness of the Polish economy – the ability of companies to innovate, create added value, and care for local values while being open to change and working towards sustainable development.
The “Polonica Progressio” competition features 6 categories: Leader of Sustainable Development, Leader of Foreign Expansion, Leader of Innovation, Leader of Technology Adoption, Leader of Management Capacity Development, and Leader of Partnership. In addition to the assessment of market position and the way in which business is developed, other important factors include the value and quality of investments made in Poland, the creation and implementation of innovations, combining a long history of business with the ability to adapt to a changing world and the implementation and promotion of measures for green transformation or building market competitiveness.
In this year’s edition, Hemolens Diagnostics was recognized as a Technology Adoption Leader and awarded the prize at the Entrepreneur Gala, held in Warsaw at the Ministry of Development and Technology. A Technology Adoption Leader is a company that is successful in creating innovative technological solutions and using them to increase the efficiency and competitiveness of its business.
Hemolens Diagnostics is a MedTech company specializing in the development and delivery of technology for personalized, non-invasive diagnostics.
With the company’s developed technology, cardiologists will be able to obtain information about the condition of a patient’s coronary arteries in a non-invasive way.
Hemolens Diagnostics is a good example of how Polish innovative solutions, created by young companies and dynamic teams, can improve quality of life and develop non-invasive diagnostics in Poland and around the world.
June 21, 2023
Physical activity plays a key role in the prevention of cardiovascular disease and other cardiovascular disorders. Research shows that...
May 26, 2023
Wrocław, April 21, 2023. – Wrocław-based Hemolens Diagnostics has been recognized in this year’s Polish Product of the Future...
March 20, 2023
Huawei Startup Academy is an initiative that was created for young, promising startups, offering them not only the opportunity...
March 7, 2023
The Start-Up-Med competition is a prestigious initiative organized by PTWP Group (Polish Association for Entrepreneurship Support), publisher of, among...
March 1, 2023
Rebranding is a process aimed at changing one or more elements of a brand’s image communication. This includes changes...
February 24, 2023
The research project ‘HEMOFLOW cloud platform for non-invasive hemodynamic diagnostics’, No. POIR.01.01.01-00-0393/19, aims to assess the diagnostic value of...
January 11, 2023
What is FFR Measuring fractional flow reserve (FFR) is currently the ‘gold standard’ in the diagnostic assessment of coronary...
November 21, 2022
On 10 November at the ISPOR 2022 Europe conference, independent research company Panaxea presented the results of a study...
Cardiolens FFR-CT Pro is a coronary physiologic simulation software for the clinical quantitative and qualitative analysis of previously acquired Coronary Computed Tomography Angiography (CCTA) and optionally with Continuous Non-invasive Blood Pressure (CNBP) data for assessment of patients with suspected Chronic Coronary Syndromes (CCS). It provides hemodynamic diagnostic factor FFR-CT (Fractional Flow Reserve with Computed Tomography), a mathematically derived quantity, computed from simulated pressure, velocity and blood flow information obtained from a 3D computer model generated from static coronary CT images and optionally from CNBP measurement. The factor FFR-CT at the output of Cardiolens FFR-CT Pro device is intended to support the functional evaluation of coronary artery disease. The Cardiolens FFR-CT Pro outputs are provided to support qualified clinicians to aid in the evaluation and assessment of coronary arteries. The results of Cardiolens FFR-CT Pro are intended to be used by qualified clinicians in conjunction with the patient’s clinical history, symptoms, and other diagnostic tests, as well as the clinician’s professional judgment.